Mentions of orphan designated drugs decreased in the pharmaceutical industry in Q1 2023
Notably, orphan designated drugs was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of blockchain and energy transition, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Horizon Therapeutics had the greatest increase in references for orphan designated drugs in Q1 2023, compared with the previous quarter. GlobalData identified 3 orphan designated drugs-related sentences in the company’s filings – 0.1% of all sentences – and an increase of 100% in Q1 2023 compared with Q1 2022. Alnylam Pharmaceuticals’s mentions of orphan designated drugs rose by 100% to 2 and Sarepta Therapeutics’s by 100% to 2 and BioNTech’s by 100% to 1 and Novartis’s by 100% to 1.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for orphan designated drugs in Q1 2023 was 152.
For further understanding of GlobalData’s New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.
Source link
#Mentions #orphan #designated #drugs #decreased #pharmaceutical #industry
